Clinical trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

NCT07510802

Study summary

ClinicalTrials.gov

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Dual-target CAR-NK cells Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lymphodepleting Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Supportive care Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-02-02

PhasePHASE1 / PHASE2

Conditions

Breast Cancer (Advanced/Metastatic)unresolved

HER2-positive Breast Cancercandidate · MONDO: HER2 positive breast carcinoma

Triple-negative Breast Cancerverified · MONDO: triple-negative breast carcinoma

Interventions

Dual-target CAR-NK cellsBIOLOGICAL

LymphodepletingDRUG

Supportive careOTHER

Sponsors & collaborators

Beijing Biotechlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07510802 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.